Trial Profile

Adverse ReNal OuTcomEs in Patients With NoN-Valvular Atrial Fibrillation Treated With Rivaroxaban or Vitamin K Antagonists

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 20 Aug 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rivaroxaban (Primary) ; Vitamin K antagonists (Primary)
Indications Thrombosis
Focus Adverse reactions
Acronyms ANTENNA
Sponsors Bayer

Most Recent Events

17 Aug 2021 According to a Bayer media release, results from this trial will be presented European Society of Cardiology (ESC) Congress 2021.
01 Mar 2021 Status changed from active, no longer recruiting to completed.
01 Feb 2021 Planned End Date changed from 31 Jan 2021 to 28 Feb 2021.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com